0001628280-24-003097.txt : 20240202
0001628280-24-003097.hdr.sgml : 20240202
20240202172550
ACCESSION NUMBER: 0001628280-24-003097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240131
FILED AS OF DATE: 20240202
DATE AS OF CHANGE: 20240202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Anzalone Christopher Richard
CENTRAL INDEX KEY: 0001423029
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38042
FILM NUMBER: 24592897
MAIL ADDRESS:
STREET 1: ARROWHEAD RESEARCH CORPORATION
STREET 2: 201 SOUTH LAKE AVENUE, SUITE 703
CITY: PASADENA
STATE: CA
ZIP: 91101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000879407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460408024
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
BUSINESS PHONE: 626-696-4702
MAIL ADDRESS:
STREET 1: 177 E COLORADO BLVD
STREET 2: SUITE 700
CITY: PASADENA
STATE: CA
ZIP: 91105
FORMER COMPANY:
FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP
DATE OF NAME CHANGE: 20040112
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE GROUP INC
DATE OF NAME CHANGE: 20020509
FORMER COMPANY:
FORMER CONFORMED NAME: INTERACTIVE INC
DATE OF NAME CHANGE: 19940224
4
1
wk-form4_1706912729.xml
FORM 4
X0508
4
2024-01-31
0
0000879407
ARROWHEAD PHARMACEUTICALS, INC.
ARWR
0001423029
Anzalone Christopher Richard
177 E. COLORADO BLVD
SUITE 700
PASADENA
CA
91105
1
1
0
0
Chief Executive Officer
1
Common Stock
2024-01-31
4
M
0
57499
14.54
A
3772547
D
Common Stock
2024-01-31
4
S
0
37769
32.16
D
3734778
D
Common Stock
2024-01-31
4
S
0
19730
32.71
D
3715048
D
Stock Option (right to buy)
14.54
2024-01-31
4
M
0
57499
0
D
2015-02-06
2024-02-06
Common Stock
57499
351726
D
The exercise of non-qualified stock options and sale was made as the stock options were approaching their expiration date. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.85 to $32.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.47 to $33.33, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
All options were fully vested and exercisable as of February 6, 2015.
/s/Christopher Anzalone
2024-02-02